1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Australia Pharmaceuticals and Healthcare Report Q4 2015

Australia Pharmaceuticals and Healthcare Report Q4 2015

  • August 2015
  • -
  • Business Monitor International
  • -
  • 137 pages

Includes 3 FREE quarterly updates

BMI View: The Australian pharmaceutical market is expected to continue on a moderate growth trajectory
over our forecast period. This is mainly explained by rising chronic disease burden as well as government funding to list new medicines under the Pharmaceutical Benefit Scheme. However, revenue opportunities for multinational drugmakers in Australia will remain limited by cost containment measures. This was accentuated in the Sixth Pharmacy Community Agreement passed by authorities in June 2015, which drives a downgrade in our pharmaceutical market forecast for the country. Among the measures outlined, the move to allow biosimilar substitution in an attempt to curb spending on biologic drugs poses additional risks to innovative drugmakers with a strong portfolio of biologic treatments.

Headline Expenditure Projections

- Pharmaceuticals: AUD13.48bn (USD12.15bn) in 2014 to AUD13.98bn (USD10.35bn) in 2015; +3.7%in local currency terms and -14.8% in US dollar terms, due to significant exchange rate fluctuations. Forecast revised downwards from last quarter.
- Healthcare: AUD151.84bn (USD136.85bn) in 2014 to AUD156.99bn (USD116.18bn) in 2015; +3.4% in local currency terms and -15.1% in US dollar terms, due to exchange rate fluctuations. Forecast revised downwards from last quarter.

Table Of Contents

Australia Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 10
Political 12
Economic 13
Operational Risk 14
Industry Forecast 16
Pharmaceutical Market Forecast 16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Australia 2011-2019) 18
Healthcare Market Forecast 19
Table: Selected Health Measures In Australia FY2015/16 Budget 20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2011-2019) 22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2011-2019) 22
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2011-2019) 23
Prescription Drug Market Forecast 24
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 26
Patented Drug Market Forecast 27
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 29
Generic Drug Market Forecast 30
Table: Cost Of Selected Drugs Post-Price Disclosure, April 2013 33
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 33
OTC Medicine Market Forecast 34
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 36
Pharmaceutical Trade Forecast 37
Table: Pharmaceutical Trade Data And Forecasts (Australia 2013-2019) 38
Table: Pharmaceutical Trade Data And Forecasts local currency (Australia 2013-2019) 39
Key Risks To BMI's Forecast Scenario 40
Macroeconomic Forecasts 41
Economic Analysis 41
Table: Economic Activity (Australia 2010-2019) 47
Industry Risk Reward Ratings 48
Asia Pacific Risk/Reward - Q4 2015 48
Australia Risk/Reward Index 54
Rewards 54
Risks 55
Market Overview 56
Industry Trends And Developments 57
Epidemiology 57
Table: Main Causes Of Death In Australia, 2011 58
Table: Percentage Of Children Immunised (October 1 - December 31 2011) 59
Healthcare Sector 59
Research and Development 61
Clinical Trials 63
Regulatory Development 65
Regulatory Regime 65
Table: Summary Of TGA Reforms 66
Table: EU And ICH Guidelines Adopted In The TGA's Biosimilars Guidance Document 68
OTC Switching Climate 69
Regional Regulatory Harmonisation 69
Recent Developments 70
Intellectual Property Issues 72
Trade Agreements 75
Pricing And Reimbursement 77
Table: Selected Drugs Undergoing SPD (AUD) 77
Table: Historical PBS Co-Payments 79
Pricing And Reimbursement Developments 82
Table: New PBS Formularies 83
Competitive Landscape 84
Pharmaceutical Industry 84
Company Developments 85
Pharmaceutical Distribution 86
Table: Top-20 Pharmaceutical Suppliers By Value From Processed PBS Prescriptions (AUDmn), ending June 2012 90
Company Profile 91
Sigma 91
Australian Pharmaceutical Industries 95
Alphapharm 98
Herron Pharmaceuticals 101
CSL 104
Mayne Pharma Group 109
Sanofi 113
GlaxoSmithKline 117
Merck and Co 123
Demographic Forecast 126
Table: Population Headline Indicators (Australia 1990-2025) 127
Table: Key Population Ratios (Australia 1990-2025) 127
Table: Urban/Rural Population and Life Expectancy (Australia 1990-2025) 128
Table: Population By Age Group (Australia 1990-2025) 128
Table: Population By Age Group % (Australia 1990-2025) 129
Glossary 131
Methodology 133
Pharmaceutical Expenditure Forecast Model 133
Healthcare Expenditure Forecast Model 133
Notes On Methodology 134
Risk/Reward Index Methodology 135
Index Overview 136
Table: Pharmaceutical Risk/Reward Index Indicators 136
Indicator Weightings 137

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.